Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Gains Conditional NYS Approval for Pediatric Disorders Array Test

NEW YORK (GenomeWeb) – CombiMatrix announced today that it has received conditional approval from the New York State Department of Health to market its CombiSNP chromosomal microarray analysis test for pediatric development disorders.

By gaining conditional approval, CombiMatrix will be able to market the test in New York while the assay is under Clinical Laboratory Reference System review. Upon completion of the review, either the test will receive full approval or additional information will be required in order to achieve final approval, the company said.

"We have focused our market development activities on our miscarriage analysis test over the past year and now we plan to expand our activity to address pediatric disorders," CombiMatrix CEO Mark McDonough said in a statement.

The New York State Department of Health granted CombiMatrix conditional approval last year to market its CombiSNP CMA test for miscarriage analysis.

CombiMatrix's tests are offered through its CLIA-compliant lab in Irvine, Calif.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.